STUDIO
BioStock Investor Meeting: Interview with Cereno Scientific
Biotech Cereno Scientific develops new treatments for cardiovascular disease, the most common cause of death worldwide. The company's lead candidate CS1 targets the rare...
RECOMMENDED READING
BioStock Investor Meeting: Interview with Cereno Scientific
Biotech Cereno Scientific develops new treatments for cardiovascular disease, the most common cause of...
Aptahem on the application to initiate clinical studies
Aptahem has submitted applications to the regulatory authorities and to the Central Ethics Committee...
